Strategic Opportunity Aviragen Therapeutics is now part of Vaxart through a merger completed in 2017, with ongoing focus on oral and gene-based vaccines. This presents a potential cross-sell for vaccine development services, such as scalable manufacturing support, vector platform optimization, or preclinical/clinical trial management collaboration.

Pipeline Foresight Three Phase II antiviral candidates (vapendavir, enzaplatovir, BTA074) indicate a robust late-stage pipeline. This creates opportunity to engage for clinical research services, biomarker strategy, regulatory consulting, and potential partnership on phase II/III trial design and execution.

Acquisition Synergy Post-merger alignment with Vaxart suggests interest in expanding oral vaccine capabilities. Target BD outreach around contract research, formulation development, and packaging/delivery optimization to support joint vaccine programs and accelerate time-to-market.

Evidence & Validation Recent preclinical signals and high antibody responses in gene-based vaccine programs indicate a demand for specialized assay development, immunogenicity analytics, and translational science services to validate and de-risk new vaccine candidates.

Market Position Operating with a lean team in a high-growth biopharma segment and revenue in the low tens of millions, there is room to propose scalable CRO/CMC partnerships, strategic consulting, and expanded manufacturing partnerships to support global vaccine deployment and expansion into respiratory virus targets.